Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics Inc. (symbol: CYTK) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of pioneering muscle activators. With a primary goal of addressing debilitating diseases where muscle performance is compromised, Cytokinetics is at the forefront of muscle biology research.
Specializing in muscle function and contractility, Cytokinetics has developed small molecule drug candidates aimed at enhancing muscle performance. The company’s innovative treatments target diseases such as amyotrophic lateral sclerosis (ALS), heart failure, spinal muscular atrophy (SMA), and chronic obstructive pulmonary diseases (COPD).
Some of the key investigational medicines in the pipeline include:
- CK-4021586 (CK-586): A cardiac myosin inhibitor showing promise in the treatment of cardiac diseases.
- Aficamten: Designed to improve heart muscle function in chronic heart failure patients.
- Omecamtiv Mecarbil: Another advanced therapy aimed at boosting heart muscle performance.
With a strong emphasis on improving the quality of life for patients with severe cardiovascular and neuromuscular diseases, Cytokinetics is committed to groundbreaking research and development. The company's strategic partnerships and collaborations support its mission to bring effective treatments to market, providing hope to patients worldwide.
Recently, Cytokinetics has been actively engaged in investor events and webcasts, sharing forward-looking statements and updates about its latest achievements and ongoing projects. The company's commitment to transparency and investor relations has established it as a reliable entity in the biopharmaceutical industry.
For more detailed updates and news, visit here, here, here, and here.
For investor inquiries, please contact Diane Weiser, Senior Vice President of Corporate Affairs, at (415) 290-7757.
Cytokinetics (CYTK) has initiated patient enrollment in REDWOOD-HCM OLE, an open-label extension study aimed at evaluating the long-term safety and tolerability of CK-274 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows the completion of the REDWOOD-HCM Phase 2 trial. The study's primary endpoint will focus on adverse events and left ventricular ejection fraction (<50%). CK-274, a next-in-class cardiac myosin inhibitor, aims to improve the quality of life for oHCM patients, an area with limited treatment options.
Cytokinetics, Incorporated (Nasdaq: CYTK) will hold its Annual Meeting of Stockholders on May 12, 2021, at 10:30 AM PT at its headquarters in South San Francisco. Stockholders of record as of March 22, 2021, can vote in person or via proxy. The meeting will feature a presentation from CEO Robert I. Blum on the company's performance. Due to COVID-19, health precautions including masks and temperature checks will be enforced. A live webcast will be available on the company's website, with an archived replay accessible until May 26, 2021.
Cytokinetics has commenced enrollment in Cohort 3 of its Phase 2 clinical trial, REDWOOD-HCM, evaluating CK-274 for hypertrophic cardiomyopathy (HCM) patients on disopyramide. This cohort aims to assess safety, tolerability, and pharmacokinetics of CK-274. Preliminary findings from earlier cohorts indicated significant reductions in left ventricular outflow tract gradients without major safety concerns. Results from Cohorts 1 and 2 are anticipated mid-2021. CK-274 has been developed to target hypercontractility in HCM, with no FDA-approved treatments currently available.
Cytokinetics granted stock options to purchase 69,800 shares to six new employees as an inducement for employment, effective April 30, 2021. The options have an exercise price of $25.44 per share, equal to the closing stock price on that date. Vesting occurs over four years, with the first quarter vesting after one year and the remainder monthly thereafter. This grant was sanctioned by the Compensation and Talent Committee and complies with Nasdaq rules. The company focuses on muscle-related drug development and prepares for regulatory action on its cardiac muscle activator, omecamtiv mecarbil.
Cytokinetics (Nasdaq: CYTK) will report its first quarter results on May 6, 2021, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM. This call will discuss operational and financial results and the company's future outlook. Investors can access the call via the company's website or by dialing designated numbers. An archived replay will be available until May 20, 2021. Cytokinetics specializes in muscle activators and inhibitors for treating diseases affecting muscle performance, with ongoing clinical trials for its drug candidates.
Cytokinetics (Nasdaq: CYTK) recently presented data on CK-274, its next-in-class cardiac myosin inhibitor, at the American Chemical Society Spring 2021 Virtual Meeting. The presentation highlighted CK-274's chemical structure, exposure-response relationship, and pharmacokinetics, particularly its projected human half-life of 2.8 days. Preclinical results indicated CK-274 effectively reduced cardiac contractility and demonstrated a favorable pharmacodynamic window. The ongoing REDWOOD-HCM Phase 2 trial is set to evaluate CK-274's efficacy and safety in patients with obstructive hypertrophic cardiomyopathy (HCM).
Cytokinetics announced that Robert I. Blum, President and CEO, will participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 3:00 PM ET. Interested parties can access the live webcast on the Cytokinetics website, with a replay archived for 90 days post-event. Cytokinetics focuses on developing muscle activators and inhibitors for diseases affecting muscle performance, currently advancing candidates like omecamtiv mecarbil for heart failure and CK-274 for hypertrophic cardiomyopathy.
Cytokinetics, incorporated (Nasdaq: CYTK), will present data on CK-274, a cardiac myosin inhibitor aimed at treating hypertrophic cardiomyopathies (HCM), at the American Chemical Society Spring 2021 Virtual Meeting from April 5 to April 30, 2021. The presentation titled 'Discovery of CK-274' is scheduled for April 9, 2021, featuring Dr. Grace Chuang. The company is advancing several clinical trials, including the REDWOOD-HCM Phase 2 study for CK-274 and the METEORIC-HF Phase 3 study for omecamtiv mecarbil, after positive results from previous trials.
Cytokinetics announced the granting of stock options for 163,700 shares to three new employees as an inducement for their employment. This includes 150,000 shares to the new chief commercial officer, Andrew Callos. The options were granted at an exercise price of $23.26, the closing price on March 31, 2021. Vesting will occur over four years, starting with 1/4 of the shares after one year. The options are part of the company's 2004 Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Cytokinetics announced a secondary analysis of the GALACTIC-HF trial, focusing on omecamtiv mecarbil's effects on heart failure patients with varying baseline ejection fractions. This data will be presented on May 17, 2021, at the ACC Annual Scientific Session. The company is preparing for regulatory discussions regarding omecamtiv mecarbil, following positive results from the Phase 3 trial. Cytokinetics is also progressing in other trials, including METEORIC-HF for omecamtiv mecarbil and REDWOOD-HCM for CK-274, a cardiac myosin inhibitor.
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
What does Cytokinetics Inc. specialize in?
What are some key drug candidates being developed by Cytokinetics?
Which diseases are targeted by Cytokinetics' treatments?
What recent achievements has Cytokinetics announced?
How does Cytokinetics contribute to muscle biology research?
Who can be contacted for investor relations at Cytokinetics?
Where can I find more detailed updates and news about Cytokinetics?
What is the focus of Cytokinetics’ investigational medicines?
What makes Cytokinetics' approach unique?
What platforms does Cytokinetics use for investor communication?
